ReviewPathogens (Basel, Switzerland)2015
Studies of Immune Responses in Candida vaginitis.
Review in Pathogens (Basel, Switzerland), 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 44 citations in OpenAlex.
- Article
- Candida albicans: the current status regarding vaginal infections.Applied microbiology and biotechnology · 2025Review
- Impact of Clove Oil on Biofilm Formation inMycobiology · 2025Article
- Prevalence ofArchives of Razi Institute · 2024Article
- Promising immunotherapeutic targets for treating candidiasis.Frontiers in cellular and infection microbiology · 2024Review
- Virulence Factors as Promoters of Chronic Vulvovaginal Candidosis: A Review.Mycopathologia · 2021Review
- Vaginal pH Value for Clinical Diagnosis and Treatment of Common Vaginitis.Diagnostics (Basel, Switzerland) · 2021Review
- The Role of B-Cells and Antibodies againstVaccines · 2021Review
- Vulvovaginal candidiasis and current perspectives: new risk factors and laboratory diagnosis by using MALDI TOF for identifying species in primary infection and recurrence.European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology · 2021Article
- Protective effect of fungal extracellular vesicles against murine candidiasis.Cellular microbiology · 2020Article
- The effect of benzyl isothiocyanate on Candida albicans growth, cell size, morphogenesis, and ultrastructure.World journal of microbiology & biotechnology · 2020Article
- Estimated Burden of Fungal Infections in Namibia.Journal of fungi (Basel, Switzerland) · 2019Article
- Mucosal Vaccine Approaches for Prevention of HIV and SIV Transmission.Current immunology reviews · 2019Article
- Biofilms Formed by Isolates from Recurrent Vulvovaginal Candidiasis Patients Are Heterogeneous and Insensitive to Fluconazole.Antimicrobial agents and chemotherapy · 2017Article
- Prevalence ofJournal of clinical and diagnostic research : JCDR · 2016Article
- Candida albicans Pathogenesis: Fitting within the Host-Microbe Damage Response Framework.Infection and immunity · 2016Review
- Total Protein Profile and Drug Resistance in Candida albicans Isolated from Clinical Samples.Molecular biology international · 2016Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The widespread occurrence of vaginal candidiasis and the development of resistance against anti-fungal agents has stimulated interest in understanding the pathogenesis of this disease. The aim of our work was to characterize, in an animal model of vaginal candidiasis, the mechanisms that play a role in the induction of mucosal immunity against C. albicans and the interaction between innate and adaptive immunity. Our studies evidenced the elicitation of cell-mediated immunity (CMIs) and antibody (Abs)-mediated immunity with a Th1 protective immunity. An immune response of this magnitude in the vagina was very encouraging to identify the proper targets for new strategies for vaccination or immunotherapy of vaginal candidiasis. Overall, our data provide clear evidence that it is possible to prevent C. albicans vaginal infection by active intravaginal immunization with aspartyl proteinase expressed as recombinant protein. This opens the way to a modality for anti-Candida protection at the mucosa. The recombinant protein Sap2 was assembled with virosomes, and a vaccine PEVION7 (PEV7) was obtained. The results have given evidence that the vaccine, constituted of virosomes and Secretory aspartyl proteinase 2 (Sap2) (PEV7), has an encouraging therapeutic potential for the treatment of recurrent vulvovaginal candidiasis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.